Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CLPT 
Clearpoint Neuro Inc (CLPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: CLPT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $29
1 Year Target Price $29
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.12% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 660.08M USD | Price to earnings Ratio - | 1Y Target Price 29 |
Price to earnings Ratio - | 1Y Target Price 29 | ||
Volume (30-day avg) 2 | Beta 1.19 | 52 Weeks Range 9.76 - 30.10 | Updated Date 10/31/2025 |
52 Weeks Range 9.76 - 30.10 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -66.15% | Operating Margin (TTM) -61.64% |
Management Effectiveness
Return on Assets (TTM) -24.52% | Return on Equity (TTM) -85.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 706021795 | Price to Sales(TTM) 19.65 |
Enterprise Value 706021795 | Price to Sales(TTM) 19.65 | ||
Enterprise Value to Revenue 21.02 | Enterprise Value to EBITDA -7.07 | Shares Outstanding 28427417 | Shares Floating 26007107 |
Shares Outstanding 28427417 | Shares Floating 26007107 | ||
Percent Insiders 8.2 | Percent Institutions 38.7 |
Upturn AI SWOT
Clearpoint Neuro Inc
Company Overview
History and Background
Clearpoint Neuro Inc. was founded in 1998 as MRI Interventions, Inc. and later rebranded. It focuses on developing and commercializing platforms for targeted drug delivery and gene therapy to the brain.
Core Business Areas
- Neuro Navigation: Provides enabling technologies and access to the brainu2019s complex networks. This includes software and hardware solutions for planning and guiding neurosurgical procedures.
- Drug Delivery: Focuses on precise, targeted delivery of therapeutics directly into the brain, bypassing the blood-brain barrier. Utilizes Convection Enhanced Delivery (CED) techniques.
- Biologics & Gene Therapy: Supports pharmaceutical companies in their development and clinical trials of biologics and gene therapies for neurological disorders. Supports partners with drug delivery systems.
Leadership and Structure
Joe Burnett is the President and CEO. The company has a board of directors overseeing strategy and governance. Clearpoint Neuro operates with functional departments focused on R&D, commercialization, and operations.
Top Products and Market Share
Key Offerings
- ClearPoint System: A neuro-navigation platform used for minimally invasive neurosurgery, enabling precise targeting for drug delivery and other therapeutic interventions. Market share is difficult to pinpoint exactly, but ClearPoint is a significant player in the MRI-guided neurosurgical navigation space. Competitors include Medtronic StealthStation, Brainlab, and others offering similar navigation solutions. Revenue generated from system sales and procedure kits.
- Competitors: Medtronic StealthStation, Brainlab
- Competitors: Multiple companies developing drug delivery technologies. No clear single competitor.
- SmartFlow Cannula: A device designed for convection-enhanced delivery (CED) of therapeutic agents directly to the brain. No definitive market share data available. Competitors include other companies developing drug delivery technologies for the brain, as well as traditional methods for treating neurological disorders.
Market Dynamics
Industry Overview
The neurosurgical navigation and drug delivery market is growing due to increased prevalence of neurological disorders, advancements in neuroimaging, and the development of new therapies. The demand for minimally invasive procedures is a significant driver.
Positioning
Clearpoint Neuro Inc. is positioned as a leading provider of MRI-guided neurosurgical navigation and drug delivery solutions. Its competitive advantages lie in its proprietary technology, strong relationships with pharmaceutical companies, and focus on precision and safety.
Total Addressable Market (TAM)
The TAM for neurosurgical navigation and drug delivery is estimated to be in the billions of dollars. Clearpoint Neuro is positioned to capture a growing share of this market through its innovative products and strategic partnerships. Exact TAM value is difficult to determine.
Upturn SWOT Analysis
Strengths
- Proprietary neuro-navigation technology
- Strong relationships with pharmaceutical companies
- Focus on precision and safety
- Experienced management team
- First mover advantage in some markets
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on regulatory approvals
- Relatively small commercial team
- Geographic concentration of sales
- Relatively long sales cycle
Opportunities
- Expanding applications of ClearPoint System
- Increasing adoption of gene therapy for neurological disorders
- Geographic expansion into new markets
- Strategic partnerships with other medical device companies
- Advancements in neuroimaging technology
Threats
- Competition from larger medical device companies
- Technological obsolescence
- Changes in regulatory landscape
- Economic downturn
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Brainlab (Private)
- Boston Scientific (BSX)
Competitive Landscape
Clearpoint Neuro has a focus in MRI guided therapies that allows it to compete with much larger companies like Medtronic and Boston Scientific. Key differentiators include its dedication to MRI-guided procedures.
Growth Trajectory and Initiatives
Historical Growth: The company has shown significant revenue growth in recent years, driven by increased adoption of the ClearPoint System and strategic partnerships.
Future Projections: Analyst estimates vary, but generally project continued revenue growth driven by expanding applications of the ClearPoint System and increasing adoption of gene therapy.
Recent Initiatives: Recent initiatives include expanding the applications of the ClearPoint System, forging new partnerships with pharmaceutical companies, and expanding into new geographic markets.
Summary
Clearpoint Neuro is a growing company in the neurosurgical navigation and drug delivery market. Its proprietary technology and strong partnerships provide a competitive advantage. While still small compared to industry giants, its focused approach and innovative solutions position it well for future growth. Close monitoring of financial health and competition is essential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- Investor Presentations
- Analyst Reports
- SEC Filings
- Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clearpoint Neuro Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2020-02-12 | President, CEO & Director Mr. Joseph Michael Burnett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 115 | Website https://www.clearpointneuro.com |
Full time employees 115 | Website https://www.clearpointneuro.com | ||
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V.; UCB Biopharma SRL; NE Scientific, LLC; and University of California, San Francisco, and Johns Hopkins University. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.